Clinical Trial Update: Trial to Reduce Cardiovascular Events With Aranesp® Therapy (TREAT) [Phase 3]

View source ↗

Summary

Phase 3 trial update for Aranesp therapy assessing reduction of cardiovascular events; study completed with results posted in 2010.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Diabetes Mellitus
• Kidney Disease

Drugs mentioned

• ARANESP (DARBEPOETIN ALFA)

Snippet

Sponsor: Amgen | Conditions: Kidney Disease, Diabetes Mellitus | Phase 3 | Status: COMPLETED | Results posted: 2010-09-02